ScholarLens Back to search
1995•Chinese Journal of Cancer ResearchRequires access

Experimental study on antitumor effect of monoclonal anti-idiotypic antibody-DNR conjugate to leukemia

Xiaolin Wang, Xifang Cao, Huifen Zhu, Na Su, Yue Zhang, Guanxin Shen

Open publisher page 0 citations

Abstract

In this experiment, the Dextran-T40 (Dex-T40) served as intermidiate carrier, conjugated SM6 monoclonal anti-idiotypic antibody (anti-Id-McAb) against B lymphocytic leukemia cells and chemotherapeutical drug daunorubicin (DNR) to form SM6: Dex: DNR immunoconjugate. The activity of anti-Id-McAb and DNR of the immunoconjugate and their extent of the substitution were measured, and the antitumor activity of SM6: Dex: DNR was assayed in vitro . The results demonstrated that using Dex-T40 to prepare immunoconjugate could get a higher extent of substitution of McAb and DNR and maintain the activity of McAb and drug well. The results of cytotoxic assay in vitro suggested that the immunoconjugate SM6: Dex: DNR possess a specific cytotoxic effect to target tumor cells.

About this research paper

What this paper is about

In this experiment, the Dextran-T40 (Dex-T40) served as intermidiate carrier, conjugated SM6 monoclonal anti-idiotypic antibody (anti-Id-McAb) against B lymphocytic leukemia cells and chemotherapeutical drug daunorubicin (DNR) to form SM6: Dex: DNR immunoconjugate. The activity of anti-Id-McAb and DNR of the immunoconjugate and their extent of the substitution were measured, and the antitumor activity of SM6: Dex: DNR was assayed in vitro . The results demonstrated that using Dex-T40 to prepare immunoconjugate could get a higher extent of substitution of McAb and DNR and maintain the activity of McAb and drug well. The results of cytotoxic assay in vitro suggested that the immunoconjugate SM6: Dex: DNR possess a specific cytotoxic effect to target tumor cells.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In this experiment, the Dextran-T40 (Dex-T40) served as intermidiate carrier, conjugated SM6 monoclonal anti-idiotypic antibody (anti-Id-McAb) against B lymphocytic leukemia cells and chemotherapeutical drug daunorubicin (DNR) to form SM6: Dex: DNR immunoconjugate. The activity of anti-Id-McAb and DNR of the immunoconjugate and their extent of the substitution were measured, and the antitumor activity of SM6: Dex: DNR was assayed in vitro . The results demonstrated that using Dex-T40 to prepare immunoconjugate could get a higher extent of substitution of McAb and DNR and maintain the activity of McAb and drug well. The results of cytotoxic assay in vitro suggested that the immunoconjugate SM6: Dex: DNR possess a specific cytotoxic effect to target tumor cells.

Key concepts: Immunoconjugate, Daunorubicin, Monoclonal antibody, Conjugate, Cytotoxic T cell, In vitro, Leukemia, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Experimental study on antitumor effect of monoclonal anti-idiotypic antibody-DNR conjugate to leukemia — Research Paper | ScholarLens